Omburtamab is a radiolabeled monoclonal antibody targeting tumor antigen B7-H3 in development for intraventricular radioimmunotherapy for treatment of neuroblastoma central nervous system/leptomeningeal metastases.
If you have a Hayes login, click here to view the full report on the Knowledge Center.